1. Primary despondent mood. 2. Inhibition. 3. Anxiety. 4. Absolute pessimism. 5. Self-reproach. 6 . Tendency to suicide. 7. Remission in the evening. 8. Poor insight into the condition. 9. Feelings of inferiority. 10. Physical symptoms (dryness of the mouth, constipation, wasting).
The endogenous depressive phase as part of manic-depressive psychosis may occur in various forms. There may be a single phase during the whole life of the patient, but this is rather rare and accurate history-taking will in all probability reveal the existence of other sub-clinical phases which were not severe enough to require medical treatment. Another form of endogenous depression is recurrent or periodic melancholia, i.e. several such phases during a life-time. These phases may resemble one another with almost photographic accuracy but they can also differ widely. The free intervals between phases may vary in length considerably, from a matter of a few days to several years. Where the depressive phases recur with almost photographic accuracy we should possess a valuable method of comparing various methods of treatment. Unfortunately this similarity of the phases usually concerns the symptomatology and not the length of the phase. Finally there is the true manic-depressive type of phase, where both manic and depressive phases occur in one and the same patient. It provides a difficult therapeutic problem, especially when one phase rapidly passes over into the other. Although severe manic phases, here as elsewhere in the world, have become less common, we find mild manic fluctuations in a large number of patients who have gone through phases of depression. The hypomanic swing at the end of the depressive phase is characteristic.
We are of the opinion that the general body of symptoms, the course of the disease and the study of heredity justify us in retaining the concept of manicdepressive psychosis. We believe that endogenous depression, just like any other psychic disease, is due to many factors. We think heredity is a more important factor in the origin of the disease than it is in schizophrenia. We agree with Kretschmer that a certain constitutional form tends to predispose towards depressive swings, but we consider the constitutional factor less marked than in the case of schizophrenia. A certain psychodynamic development also appears to be necessary and we think that here the first disturbances already occur in the second oral phase. The family situation is also often characteristic. We know the mother of the manic-depressive patient, just as we know the mother of the schizophrenic. She, too, is a domineering mother, less anxious but much more exact and pedantic and subject to greater fluctuations in mood than the mother of the schizophrenic.
Finally, in the production of depression some precipitating factor is necessary which is usually much more clear than that which precipitates a schizophrenic episode. This precipitating factor has to strike in a critical phase of the patient's life. It is clear therefore why the commencement of an endogenous depression often coincides with a critical period of life such as puberty, completion of social development (between the ages of 20 and 24), involution and old age.
We must stress the fact, however, that with repeated attacks the precipitating factor recedes more and more into the background. This is probably due to a much greater participation of the vegetative nervous system, which evokes the same reactions in a preformative manner.
'In assessing endogenous depression we must not ignore the situation of the patient nor the influence of the depression on his surroundings. We know that the melancholic patient irritates and depresses all around him and is then further depressed by their reaction to him.
We have mentioned all the multiple factors which playa part in the origin of endogenous depression, and they are certainly important. But we should not stress anyone factor too much and lose sight of the whole since this would result in a confused diagnosis.
Some forms of depression may be difficult to classify into one of these groups, and only the further course of the condition clarifies the diagnosis. Moreover, all manner of combinations are possible, e.g. a reactive depression which passes over into a true endogenous depression or one in which both a neurotic and endogenous component are .present. However, in the great majority of cases classification under one or other of the groups mentioned is possible and is a decisive factor both for prognosis and therapy.
What is characteristic of endogenous depression? We believe that healthy persons under certain circumstances may be just as sad, anxious and pessimistic as the endogenous depressive patient. But two phenomena are characteristic of the latter. One is the persistence of the depressed mood, the fixity with which it is maintained, visible in the emotional and vegetative reactions as well as in the movements. The other phenomenon, only seemingly an antithesis of the first, is the possibility of a sudden switch in a matter of seconds to the opposite mood, a manic state. This sudden switch, which is never quite so dramatic in normal persons and can be seen for a short time in almost all true endogenous depressions, involves all levels of the personality and is particularly manifest in the vegetative S57 sphere (Selbach's "Kippreaktion"), These two phenomena help to confirm the diagnosis of endogenous depression.
This differentiation among the various forms of depression provides us with indications as regards therapy.
Exogenous depression due to obvious external stress can only be helped by reducing this stress or by just being humanly helpful. The doctor can do more here by friendly assistance than by any medical treatment. Indeed it is a moot point whether drugs can do such patients any good since they get the impression that they are ill, whereas in reality they are merely displaying a normal reaction. Any improvement in an exogenous depression brought about by drugs is probably purely suggestive, and can be attributed to the personal relationship between doctor and patient.
In neurotic depression treatment must be aimed of course at the basic symptoms of neurosis. Psychotherapy is here the treatment of choice. If the secondary depression renders the patient unresponsive to psychotherapy then in some cases drugs may be helpful. The patient must be clearly told, however, that the drug is only for the secondary depression and is purely supportive treatment. There is one danger here, that side effects resulting from the drug may be employed as conversion symptoms by the patient. This is important with drugs such as the neuroleptics with their pronounced vegetative side effects. We are of the opinion that in neurotic depression drugs should only be used with the utmost circumspection and only when the psychotherapeutic contact is good.
In endogenous depression the situation is quite different. We have seen that endogenous depression is at least in part due to organic conditions or is organically fixated. It also responds to organic therapy. We are not yet in a position to carry out a causal therapy because we know nothing of the nature or localization of the disturbance. We can therefore attempt by symptomatic treatment to shorten the phases of the disease or at least mitigate the symptoms.
Twenty years ago, thanks to the discovery of Cerletti and Bini, electroshock therapy (ECT) was introduced into the treatment of depression. To avoid misunderstandings we must first say a few words about the technique we employ today and the relative risks involved. We always use muscle-relaxants in conjunction with electroshock, and for some considerable time we have been employing succinylcholine chloride, the use of which in ECT was first described in Vienna. We either use small doses (8-10 mg) to prevent bone fractures, which we call mitigated shock, or we use rather high doses (60-100 mg) combined with intravenous anaesthesia and artificial respiration, which we call fully mitigated shock. We employ fully mitigated shock where otherwise there would be medical or surgical contraindications for the use of ECT. Fully mitigated shock, which can be carried out by a doctor and one nurse exactly like normal ECT, should only be performed by a doctor fully trained in anaesthetics and with considerable experience of ECT technique. Almost all accidents which occur during shock treatment are due to some technical error.
We recognize no medical or surgical contraindication for ECT apart from recent cardiac infarction. The dangers of ECT, so often stressed, seem to us extremely slight, in fact less than those of almost any drug treatment in psychiatry. In the past five years, out of a total of about 15,000 electroshocks, of which 2000 were fully mitigated, we had not only no death but no complications at all. We never had to interrupt shock treatment because of complications.
How does ECT act in endogenous depression? We believe that electroshock destroys the tendency of endogenous depression to become fixated, and does this at all levels of the personality. The individual shock momentarily changes the activity of all centres in the brain and the normal metabolism of the cells has to be S58 CANADIAN PSYCHIATRIC ASSOCIATION JOURNAL Vol. 4, 1959 slowly re-established. In the vegetative system a maximum stress occurs, with all the features of the stress phenomenon. The vegetative system only gradually swings back into the normal state and the process may take several days. The 'end effect is that the sympathicotonic component of the vegetative system is reinforced, which benefits the more vagotonic depression. The whole content of the psyche is obliterated and patients wake confused out of the shock, remain amnesic for hours and have to collect their psychic content again laboriously. This process is of relatively short duration after the first shock, but after repeated shocks takes longer and longer.
The effectiveness of ECT depends to a large extent on subsequent shocks being given at the correct moment. The next shock must be given before the depression has again become fixed at all levels. This produces a summation of effect. ECT is therefore only effective when applied in a series at short intervals. At the commencement of treatment 48 hours would seem to be the maximum permissible interval. After several shocks, when the amnesic interval lasts longer, the time between shocks can be increased to three days and in older patients possibly to four days, but not longer. The amnesia is part of the action of ECT. All attempts to lessen it or avoid it impair the effectiveness of the treatment. Amnesia occurs in fully mitigated shock just as much as in unmitigated shock. Bad results with ECT are usually due to an insufficient number of shocks or to irregularity in the treatment. Excessive prolongation of ECT is also not right. Patients can get used to ECT just as they do to drugs. There are patients who can talk intelligibly and coherently five minutes after an electroshock, particularly if they have received a great number of shocks at irregular intervals.
If a series of six up to a maximum of twelve electroshocks proves unsuccessful, they must be stopped and another series given only after an interval of some weeks to several months (this of course only applies to endogenous depression, not to schizophrenia). Successes with ECT in typical endogenous depression, and indeed in all forms of depression, attain the very high proportion of over 80%. The occasional failure of ECT leads us to question the diagnosis, when we nearly always find encephalographic evidence of cerebral atrophy. ECT is also less effective where there is a big neurotic component in the depression, and also when external difficulties persist and give it an exogenous basis.
At the end of every successful shock treatment we try to follow up with psychotherapy of course, in order to treat those factors arising in the patient's own psyche which predispose towards a relapse, but here we meet with difficulties. Once cured, the patient with endogenous depression feels perfectly well and wants to hear no more of his illness. His attitude is quite different from that of the schizophrenic. The schizophrenic may show some insight into his condition and he often makes an attempt to understand the morbid phenomena. He is therefore particularly amenable at this stage to psychotherapy. The patient with endogenous depression is different, has no understanding of his symptoms and cannot see why he should continue to be treated. The attitude is different when there is a neurotic element in the depression and it is then easier to follow up ECT with psychotherapy.
We have not therefore had very satisfactory results with psychotherapy in endogenous depression, but we are still looking for a solution.
The shock treatment of endogenous depression is very successful and is certainly one of the most successful forms of therapy in the whole field of medicine. In spite of this, attempts are always being made to force its abandonment. This attitude is understandable on the part of patients and relatives. There is a common fear of the term "shock" and of an electric current, and of a permanent damage to the personality. Many patients think their minds can be permanently affected or memory impaired. Many patients find the idea of going to hospital for shock treatment unpleasant. ECT for out-patients 'is fraught with difficulties and we think it can only be done exceptionally and with special precautions. This fear of ECT and of hospitalization results in many patients with endogenous depression not going to the doctor at all, and then being committed forcibly to hospital in a much later stage of the illness or following a suicide attempt. This state of affairs has improved somewhat in recent years but is still unsatisfactory.
Any treatment, therefore, which could replace ECT and did not have these disadvantages would be welcome. In this respect the new drug Tofranil* seemed to offer possibilities. I would now like to report on our experience with this drug and also draw some conclusions from it of use for the further therapy of depression.
I will not take up your time with a repetition of the chemical and pharmacological properties but will merely point out that the similarities of the nucleus with that of phenothiazine and .of the side chain with that of chlorpromazine suggest a similar action.
This resemblance is, however, only partial. Our doctors, by trials on themselves and by exact questioning of patients, have attempted to establish in the first place the action of a single large dose (50-100 mg) of Tofranil on the psyche. There was general agreement that Tofranil, after a latent period of about half an hour, causes a sense of tiredness and of distance, similar to that produced by phenothiazines but much less. A second component was a certain inner restlessness, or as one of my doctors put it, an "inner quivering." The total effect was like the feeling one has when one is over-tired and unable to get to sleep. It is interesting that none of the healthy test persons found any euphoric or stimulating effect. On the other hand, many patients with endogenous depression state that they feel a distinct improvement in mood and capacity to work.
When used for a short course of treatment, Tofranil acts on the basic depressive mood and inhibition. A general activation takes place, the patients get up earlier in the morning, are prepared to work, their movements become more brisk and the facial expression loses the tense rigidity of the depressive. Patients acquire a sense of distance from their depressive symptoms, similar to that which neuroleptics provide in the case of schizophrenic symptoms. There is no direct effect on a number of depressive symptoms such as hypochondriacal ideas, agitation or anxiety; on the contrary agitation is often reinforced. Nor are schizophrenic symptoms, particularly delusions and hallucinations, affected.
For out-patients we chose a dosage of 150-250 mg per day and we always tried to give the highest dose which could be tolerated without causing side effects or impairing the capacity to work.
In hospital we usually commenced with injections, increasing in the course of 3-4 days to a total amount of 150-200 mg, then gradually replacing injections by double the amount by mouth. We usually reached in this way a dose of 300 mg per day which was gradually reduced after the symptoms of depression had disappeared, leaving a maintenance dose of about 150 mg per day. We often began with tablets from the outset and increased the dose within a matter of days from 150 to 300 mg per day. Results did not seem to depend absolutely on the size of the dose. We often noticed that if a dose of moderate size was of no avail, increasing it did not necessarily bring success.
The drug was well tolerated by those patients who displayed no untoward side effects. Initial tiredness soon disappeared, so that patients could work while undergoing treatment. There is little effect on the circulation, although occasionally mild tachycardia was seen. We have seen no case of collapse, but since several have been *Trade Mark.
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Sleep is improved in about two-thirds of cases and rendered less good in onethird. This variable reaction is explained by the two component actions which we discussed earlier. Where sleep is poor, Tofranil may be combined with hypnotics or possibly with chlorpromazine. We should add that Tofranil can be combined with any other drug and also with electroshock.
We have treated a total of 120 patients with Tofranil in the last 8 months. In 31 of them, that is in roughly one-quarter of the cases, we observed untoward side effects or complications. In 12 cases therapy had to be discontinued for this reason. Table 1 summarizes the side effects and complications. Some side effects such as dryness of the mouth and increased secretion of sweat are very common, but are not found to be particularly distressing. A feeling of weight in the abdomen, nausea and constipation are often mentioned but should be treated with reserve in a condition like depression. Giddiness and tachycardia depend on the dose and can be ameliorated by reducing it. In five cases we saw a transient exanthem which disappeared again two days after interrupting treatment and in two cases did not reappear after recommencing Tofranil. The exanthem was not accompanied by any other allergic phenomena. The very fine tremor observed in 8 cases was interesting. It was quite different from the coarse parkinsonian-like tremor associated with phenothiazine or reserpine. Two patients treated for a relatively long time with rather high doses showed first an intensification of the tremor and then pronounced choreiform twitchings. We examined these cases clinically and electromyographically in detail and believe there were lesions of the ascending fibres in the reticular formation of the brain stem, but we cannot go into this in greater detail in this paper. The twitchings disappeared two or three days after discontinuing Tofranil. An unpleasant effect was total retention of urine in two cases, necessitating indwelling catheters. It persisted in one case one week after stopping T ofrani I and in the other three weeks. Weare not sure, however, that in the second case, a woman patient, the disturbance did not become psychically fixated. This retention of urine, which was accompanied by a peculiar frontal picture and crossing of the legs when walking, reminded us of the cases of centrally originating retention of urine following lesions of the basal parts of the caudate nucleus described by Harburg. It may provide a hint as to one of the sites at which Tofranil acts. Interference with accommodation, seen in three cases, was very similar to that caused by phenothiazines. One case of icterus oc- cur red during treatment, but since it showed all the signs of an infectious hepatitis it probably had nothing to do with Tofranil, Tofranil is thus seen to cause relatively frequent side effects but these are in general not particularly dangerous. Severe permanent damage or death did not occur during our treatment.
And now a word about our results with Tofranil, Out of our 120 cases we have chosen 83 for evaluation. In the other cases treatment had to be discontinued either because of side effects or for other reasons. The cases are classified according to diagnosis in Table 2 . A glance at this table shows that real remissions were only obtained in true endogenous depression. In all other conditions only the concomitant depressive symptoms were improved, while the underlying disease was unaffected.
In Table 3 we have summarized our 50 cases of endogenous depression. The four columns show the various grades of improvement. Column 1 contains the completely negative results, cases which did not respond to treatment at all. Column 2 gives the cases which responded well initially but then relapsed so that Tofranil no longer had any effect. Column 3 contains the majority of cases, those responding markedly to Tofranil with improvement both in the depressive mood and in the inhibition, but without full remission. We were able to discharge some of them from hospital but they were not fully capable of work. As soon as Tofranil was discontinued the depression got worse and the drug had to be given again. In these cases there is only symptomatic improvement, the condition becoming more tolerable for the patient while waiting for the depressive phase to pass spontaneously. Interestingly enough, there were four patients in this group with chronic endogenous depression who had responded to no treatment at all and even with electroshock showed only transient improvement. They did not remit fully, but they felt much better than they had for years.
Column 4 contains the complete remissions. They usually occurred relatively quickly between the 3rd and 14th day. Very slow gradual improvement is usually followed by a less favourable end-result than a rapid change in mood. In four cases we saw a subsequent typical hypomanic swing. Remission was maintained even Vol. 4, 1959 after discontinuing Tofranil, Detailed study of the case histories of these patients, some of whom we knew from previous phases, convinced us that the remissions were not just spontaneous or accidental but a genuine effect of the drug. The table shows that patients who are sad, apathetic and inhibited respond better than agitated or hypochondriac ones. In four senile depressions there was no success. We are aware that this figure is not significant, but in general it seems to us that with increasing age the efficacy of the drug diminishes and the side effects increase. We believe the drug should not be employed in arteriosclerosis and cerebral atrophy because the effect is too small to warrant the risk of complications. The best indications for Tofranil are therefore the more inhibited forms of genuine endogenous depression. In this group the effect is better the less severe the depression. When the inhibition is very severe (substupor or stupor) Tofranil has usually no effect. In this selected group of endogenous depressions, we had in about one-quarter full remissions and only in one-fifth complete failure. These figures agree well with those of other authors. One can thus conclude that about onequarter of the patients will show complete remission, about one-half will be improved and another quarter will not respond. Taking complete remissions and improvements together, 75% will respond to treatment. Now what of the mode of action of Tofranil? We must admit that with this drug too, practice is in advance of theory and that we possess only the vaguest of notions about its mechanism of action and site of action. We believe that in analogy to phenothiazine there is an effect on the ascending fibres of the reticular formation. We would like to mention the three functions of the tectoreticular formation: the motor function guaranteeing upright posture, the vegetative function coordinating a number of the most important vegetative centres, and the function which causes the brain to react sensorially and emotionally to external stimuli. We know that all these functions are disturbed in endogenous depression, but we also know that in man part of the function of the reticular formation, especially as regards dealing with emotional contents, has been taken over by the thalamus, and we believe that Tofranil acts on the thalamus.
Since Tofranil has been found to exert a specific effect on the depressive mood and inhibition we may hope that better knowledge regarding the site of action of this drug will lead to new insight into the mechanism of depression.
Before comparing the effect of Tofranil and electroshock we should perhaps say a few words about another drug which in recent years has proved valuable in a number of depressive states. We refer to iproniazid, with which we have not had much experience, but sufficient to form an idea of its effect when considered in conjunction with the literature on the subject. The action of iproniazid seems fundamentally different from that of Tofranil, Iproniazid seems to have no direct effect on the depression but to be a genuine euphoric. It improves the mood not merely in depressive patients but in normal persons too. A consequence of this is that iproniazid seems least successful in true endogenous depression but has some value in depression with a neurotic basis. But we must once more warn against the misuse of drugs with a euphoric effect in neurotic depression. Iproniazid also possesses very unpleasant side effects and in some cases leads to severe jaundice which may terminate fatally. We do not yet know whether its effect justifies its use on a wider scale. However, like Tofranil, iproniazid might provide valuable insight into the mechanism of psychic disturbances. Studies to date on the inhibition of monamine oxidase and the resulting effect on serotonin and noradrenaline metabolism are very promising.
Finally we would like to compare the effects of Tofranil and electroshock (ECT). These may be summarized as follows:
1. First the indications: ECT has many more indications than Tofranil, and just those cases which are indications for Tofranil react best to ECT. It is therefore not possible to work out a differential indication, i.e. in one group ECT and in another T ofrani1. 2. The number of remissions is three times higher with ECT than with Tofranil when only full remissions are taken into consideration. 3. Time is an important factor in hospital. We lose a lot of time with unsuccessful Tofranil treatment, since we then have to give ECT anyway. 4. The quality of the remission obtained with Tofranil seems to be just as good as that with ECT for any single phase. Nowhere of course has the follow-up time been sufficiently long to say much about relapse. This point seems of some significance because patients who remit with Tofranil have the advantage of suffering no transient loss of memory. 5. As regards the risks, Tofranil offers more risk than ECT since side effects and complications are much more frequent than with ECT. Tofranil can be employed in combination with ECT either simultaneously or subsequently. Simultaneous combination has not proved of value to us since remissions were neither more rapid nor better than with ECT alone. Furthermore, after unsuccessful Tofranil treatment we were not able subsequently to reduce the number of electroshocks. On the other hand Tofranil proved very valuable for the aftertreatment of depression following ECT. Sometimes, particularly after insufficient shock treatment, there remained residual fluctuations in mood or an irritable dysphoric mood but these symptoms responded excellently to Tofranil in 8 cases.
Now what of the further indications for Tofranil r These may be summarized as follows: Out-patients: 1. All cases of endogenous depression not endangered by risk of suicide. 2. Mood fluctuations following treatment with electroshock. In-patients: 1. Endogenous depression, mainly inhibited. Trial treatment for 8-14 days.
No success with chronic depression.
The last three indications in this table follow automatically from what has already been said. In hospital and with the right indication we would first make a short trial with Tofranil and then relatively soon, if this fails, change over to the more promising ECT. Tofranil may bring improvement in cases which responded to no other treatment. We have already discussed after-treatment following ECT.
Let us turn finally to the important question of the ambulant treatment of endogenous depression. This is a dangerous malady with a mortality, if one excludes that of senile dementia, six times greater than that of all other psychic illnesses put together. This is due to the high proportion of suicides. We know that there is no case of endogenous depression which at one time or another is not liable to the risk of suicide and that the danger is greater when the depression improves because of the disappearance of inhibitions. The doctor who treats an endogenous depression outside hospital thus carries full responsibility for the life of his patient. Every successful suicide of such a patient must be looked upon as an error of judgment on the part of the doctor.
Here I would like to express the hope that all doctors be aware of the seriousness of this risk, so that the use of the new drug Tofranil, which certainly represents a valuable addition to therapy, may not lead to an increase in the number of suicides in endogenous depression.
For us in Vienna the challenge is not so much the interruption of the depressive phase as the prevention of a relapse. In this respect Tofranil presents us not only with a problem but with a hope for the future. Vol.4,1959 Resum.e L'auteur decrit les formes principales de depression: psychoreactive ou exogene, due it des circonstances exterieures defavorables; depression nevrotique, apparaissant au cours d'une nevrose, et provoquee par la reaction de la personnalite; depression endogene proprement dite, faisant partie des psychoses maniaques depressives. La psychotherapie constitue le meilleur traitement des deux premieres formes, ou les medicaments sont, dans I'ensemble, it deconseiller. Dans le traitement de la depression endogene, l'electrochoc remporte ses meilleurs succes, mais, vu la prevention generale qui s'attache it tous les traitements par choc, une therapeutique de remplacement serait la bienvenue. Le Tofranil semble offrir cette possibilite.
L'auteur decrit I'action du Tofranil et en discute les dosages. Un quart environ des 120 patients traites ont presente des effets secondaires desagreables qui, 12 fois, ont necessite une interruption de la medication. Ces effets -en general peu graves sont examines. Dans quelques cas, la localisation possible de lesions dans le systeme nerveux central est discutee en detail, en ce sens qu'elles permettent de se faire une idee du point d'action du Tofranil.
Les En milieu hospitalier, et une fois l'indication correctement posee, l'auteur propose de faire d'abord un court essai (8-14 jours) au Tofranil, et en cas d'echec, de passer it la therapeutique par le choc. Le Tofranil peut apporter l'amelioration, lil. ou toutes les autres methodes ont echoue. En clientele libre, la prudence est de mise, du fait que la depression endogene comporte un gros risque de suicide.
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of endogenous depression, and more particularly in patients in whom the main presenting symptom is inhibition. These findings are consistent with those of other research workers, such as Lehmann (1) Fazio (2), Kuhn (3) , and find confirmation in Mann's research (4) on 80 cases treated with Tofranil during the past year at the Montreal General Hospital. Azima and Vispo (5) , of the Allan Memorial Institute of Psychiatry in Montreal, however obtained equally as good a response in neurotics as in psychotic depressions; and in my experience 4 cases of obsessive compulsive personality suffering from severe reactive depression benefited from Tofrjinil therapy. These patients had such a rigid personality structure that they proved unapproachable to psychotherapy. Prior~o Tofr~nil, siIIl:ilar. cases would have been .treated with electroshock therapy because of their obsessive SUICidal rummanons, In two of them the Improvement after only a few days on Tofranil was such that psychotherapy became possible. Another patient, a woman of 38, became extremely depressed because of sudden panic attacks of hysterical nature, which made it impossible for her to go to church or to go out in crowds. The symptoms had been present for years -indeed for over 15 years she had been unable to go shopping by herself, and could only do so when accompa~ied by a friend. Tofranil removed the depression, her panic states decreased in intensity and frequency and the patient is now undergoing psychotherapy. This brings up the difficulty and complexity of assessing what has produced the improvement, pharmacotherapy or psychotherapy -or better still, how much is the improvement due to one or the other or to both. Another difficulty in assessing the results of treatment is the classification of depressions. There are a large number of depressions which do not allow a clear-cut differential diagnosis: for instance, neurotic depressions and endogenous depressions. There are many depressions which are of mixed type, or atypical. Generally speaking, one may state that the precipitating factors of depressions represent either a loss of self-esteem or a loss of supply which, to the patient, would secure or even enhance his self-esteem. There are experiences which, even for a normal person, would imply loss of self-esteem, such as failure, loss of prestige, loss of money, a condition of remorse, or experiences which entail a loss of some external supply, such as disappointment in love or the death of a beloved one. Further, there may be tasks which the patient has to fulfill and which may make him more aware of his inferiority.
Even experiences that for a normal person would mean an increase in self-esteem may precipitate a depression if the achievement produces in the patient the fear of punishment or of further imposition or guilt. A case in hand is that of a 55-year-old successful chartered accountant who, two weeks prior to his admission to hospital for a severe depression, had been nominated to a very important position. His success suddenly and acutely led him to feel overwhelmed by feelings of inadequacy and despondency. He lost all interest in his job, complained of difficulty in concentration, became agitated and anxious, lost 9 lb. in weight in a fortnight, suffered from disturbance of his sleeping pattern, waking up early in the morning and lying awake ruminating about suicide. This patient was placed on Tofranil up to a maximum of 200 mg per day. There was little change in his depression for the first few days; indeed, his agitation increased, necessitating the addition of chlorpromazine, 25 mg t.i.d, By the fifth day, however, there was noticeable lifting of the depression and two weeks after admission to hospital he was discharged.
Other cases of depression due to decompensation of obsessive compulsive defenses have not reo sponded to Tofranil.
The borderline between neurotic depressions with the patient's ambivalent relationship to external objects in his quest for narcissistic supplies, and psychotic depressions where the conflict has become internalized, is not a sharp one. The increased need of narcissistic supplies by the depressed patient leads to the feeling, "nobody loves me," but the latter does not often lead to the feeling "everybody hates me." Indeed, in the classic depressions, the feeling is the opposite: namely, that they are not hated enough, the characteristic position being not so much "everybody hates me" as "I hate myself." Delusions of being hated by everybody occur more frequently in cases of depressions with paranoid traits. Tofranil appears to be much less effective in the latter cases.
Dr. Hoff reported three cases of alcoholic depressions treated with Tofranil with poor results. I have treated one case of alcoholic depression with equally poor results: namely, a business man of 58 who, off and on for the past 20 years, has been subject to alcoholic sprees of 7-10 days duration, with an average daily consumption of alcohol of 40 oz. These alcoholic sprees coincided with depressive phases, his normal mood being mildly hypomanic. Time does not allow me to go into the psychodynamics of the case. Suffice it to say that his last alcoholic' bout was precipitated by his wife remonstrating at breakfast to his asking for two pieces of toast instead of the usual one, and his daughter chipping in, "you know you never eat two pieces of toast." As a child he always felt that nobody was really interested in him. He stated that his "pet hates" were "apple cores, cigarettes in ashtrays or in coffee cups, Kleenex left around." On his last admission he presented the symptoms of an endogenous depression, and he was treated with Tofranil-treatment which he soon gave up because of the side effects: namely, sweating, particularly of the face.
As mentioned by Dr. Hoff, perspiration appears to be a frequent complaint by patients on Tofranil, Statements such as "perspiration pours down my face like water," or "I perspire gallons of water," are quite common. It is rather interesting, when one inquires about the site of perspiration, that the great majority of patients complain of perspiration of the face and not so much of perspiration on the rest of the body, such as axillae, hands and feet. Two of my patients actually denied perspiring in any other part of the body except the face.
Side effects do not always prove to be of nuisance value. Indeed, I can mention one case in which one side effect proved to be beneficial. This was in a female patient of 47 who was subject to phases of depression. Her sister is beset by phobias and is alcoholic. Her brother is a manic depressive of the cyclic type. There is also a history of allergy in the family, her father having asthma and her mother's brother chronic bronchitis. The patient herselfis sensitive to drugs such as penicillin, though no specific sensitiv- VoIA,1959 ity was elicited by the usual skin tests. When seen by me she was quite depressed, and unable to carry on with her job. She was prescribed Tofranil and within two weeks not only the depression lifted, but her 'allergy' also vanished. "I'm not sick at all-I'm myself again. I don't understand it because my problems are still there. I am sleeping well. My appetite is good -such a relief to be able to eat. My allergy is cured. My nose used to run all the time, my eyes swell, they would water, and people 'in the office always thought that I had a cold. They would say 'you can't work like this -go home.' " R. Mann, in a personal communication, reported similar good results in a female patient with sensitivity to several allergens. This is not surprising since in some patients allergic symptoms are in the nature of depressive equivalents. Dancey, also in a personal communication, reported prompt response to Tofranil in two cases of chronic and intractable diarrhoea.
Pharmacotherapy is indeed opening new channels of discovery to the research workers in psychiatry. Tofranil, if taken in large amounts, that is, well beyond the usually recommended therapeutic doses, can be very toxic. A female patient of 21, suffering from a character disorder and a depressive reaction, attempted suicide by ingesting 100 Tofranil tablets as follows: at 7:45 p.m. she ingested six 25-mg tablets; between 8:00 and 8:30 p.m, she had tea and toast; at approximately 8:45 p.m. she ingested the rest of the bottle containing 100 tablets. She reported this at 9:15 p.m., at which time she was slightly drowsy but fully conscious. Gastric lavage was done, and when the gastric tube was inserted the patient began to vomit. Inspection of the vomitus revealed no intact tablets. Following the lavage the patient apologized for causing so much trouble, thanked the doctor and walked unaided to her room. At 10 p.m, she became unconscious. The colour was &ood, the skin was pale, warm and dry, but the mucous membranes were moist. Blood pressure was 90/50 (normal for this patient), pulse 120 per minute, full and bounding. Both arterial and venous pulsations were strikingly visible in the neck, respirations were 32 per minute, deep and stertorous. Patient was stuporous but responded to any stimulation by becoming restless. When her name was called she would open her eyes and stretch her arms, with marked ataxia, but made no sound. She withdrew briskly from any stimulation. Any stimulus, sound, skin stimulation, even the room light] would increase her restlessness and agitation. The pupils were dilated, but responded to li~ht with a brisk but small contraction. Deep tendon reflexes were all markedly hyperactive, but were bilaterally symmetrical. It was difficult to be sure, because of the brisk withdrawal response, but bilateral Babinski responses appeared to be present.
Vital signs were recorded every 15 minutes throughout the night. During the next hour the level of consciousness seemed to decrease and the sensitivity to stimuli to increase. At 11 p.m. while being examined, the patient had a typical tonic-clonic bilateral symmetrical grand mal seizure, lasting between 5-10 seconds. This appeared to be directly related to the skin stimulation during the examination. Respiration was resumed immediately after the cessation of the convulsion. It was shallow for the first few breaths, then deep and regular. The patient was much quieter after the seizure. To prevent further seizures she was given gr. 772 of sodium amy tal intramuscularly. The room was darkened and the patient was kept as quiet as possible. At 12:30 a.m. the blood pressure was 80/50, and pulse was 100. Respiration had fallen to 22 per min. By 1:30 a.m. the blood pressure had risen again to 90/50, and the pulse to 110 per min. Respiration had fallen to 20 per min., and excursions were normal. They remained so from then on. At 2 a.m, she would open her eyes when called by name. At 3.30 a.m, she would move her arms and legs when spoken to, and at 6 a.m, she was awake, complainin~that her arms were stiff and painful, and asked for a drink and a cigarette. She was given a drink of JUIce and she complained of sore throat. She remained drowsy throughout the followin~day, but was easily roused and well oriented. Slight ataxia of the arms was noted, intermittent choreiform movements of the arms and about the mouth were observed. She was given sodium amy tal gr. 1 p.c. t.i.d. Temperature was not recorded during the acute phase of the poisoning but the following day it was noted to be slightly above her normal baseline, reaching a maximum of 99.4°. Thirty-six hours after the ingestion of the Tofranil the patient appeared to have completely recovered. Her only complaint was a pain and tenderness in both biceps tendons, which may have been related to the seizure. At this time she was questioned as to what she remembered about the event after she took the pills. The last thing the patient remembered clearly was telling the nurse that she had taken the pills. In spite of the fact that she had talked to the doctor after the gastric lavage, her only memory of it was a vague recollection of seeing the tube with a bulb on it. Analysis of the urine specimen revealed the presence of free Tofranil. In this case it is impossible to say how much of the drug was actually absorbed. It seems safe to assume that it was much larger than the usual therapeutic dose. ( In the past four months we have had 4 cases with leucocytosis and shift to the left with toxic granulations.
Age need not be a contraindication to Tofranil therapy. A male patient of 76 was admitted to hospital suffering from a depression. He suffered also from diabetes, hepatomegaly of undetermined origin, non-specific colitis, diverticulosis of the colon, and external hemorrhoids. In his regression, like a hungry infant, he was extremely demanding towards the nurses, doctors, residents and patients. The need for narcissistic supplies was so intense that even in an all-giving environment it soon produced rejection and consequently more regression. He was placed on Tofranil therapy and after two weeks he became somewhat euphoric. Incidentally, in this case, there was also evidence of cerebral organic changes with electroencephalographic findings.
Organic cerebral pathology need not be a contraindication to Tofranil therapy, as illustrated by a female patient of 66 who, throughout the past 10 years, has required several admissions to hospitals and mental institutions, and several courses of electroshock therapy. Her blood pressure was more or less stabilized at 200/130, with left ventricular hypertrophy. She had been treated for recurrent depression for the past 30 years, and in later years the depressions tumbled over each other with ever-increasing speed. Following are the list of admissions since 1954 -August, 1955 February, 1956; July, 1956; February, 1957; August, 1957; December, 1957; June, 1958 . She had to be treated with a course of electroshock therapy on each occasion, her husband refusing to have her committed. In 1953 she had a stroke and again in 1957. She believed in faith healing and on every occasion she refused to be admitted to hospital until she had to be practically carried into the hospital by her husband because of her extremely acute condition. On her last admission on June 26th, 1958, she was prescribed Tofranil, 50 mg intramuscularly b.i.d. She was totally negativistic and was given five ECT's to make her more manageable and cooperative. Her depression lifted and was replaced by arthritis. She was discharged one month later "recovered". She has been well ever since, her maintenance dosage being 100 mg daily.
From the above one might gather the impression that I am a Tofranil enthusiast, and indeed I have seen some remarkable "cures," but I am too conservative to be an enthusiast about any form of drug therapy. In the past 10 years enthusiasm has waxed and waned about the discovery of any new drug. In the field of medicine ACTH and cortisone, when first discovered, were supposed to cure all, until one found that they did not remove disease but only suppressed it. Tofranil appears to do exactly that in the case of endogenous depression, since it is recommended that the drug be used as long as the natural course of the depressive episode is thought to last. If therapy is discontinued prematurely during the active phase of the depression, the symptoms may recur. When chlorpromazine and promazine came on to the market they also were supposed to be cure-ails until, through diligent investigation and experience, it was found what they were good for and what they were not good for. It is my opinion that the same phenomenon will take place in the case of Tofranil. It is my opinion that over-enthusiasm may actually lead to disappointment which, in turn, may by over-reaction lead to non-usage of-the drug, even in cases in which the drug could be most effective. Perhaps, with further research, we will be able to relate the efficacy or lack of efficacy of Tofranil to the psychopathology of depressions. We must not lose sight of the fact that depressive illnesses, though very common, represent only a fraction of all psychiatric disorders, and psychiatry may lose out from too tosy promises to the public of easy cure of mental illnesses.
I enjoyed listening to Dr. Hoff's presentation. His conservative outlook finds an echo in my thinking.
personal reactions were more important. Now, however, since a treatment has become available, diagnosis is essential. Dr. Hoff agreed that iproniazid has an effect on every kind of depression, while Tofranil is effective only in endogenous depressions, but felt that a new drug, similar to iproniazid but less dangerous, may soon become available. Endogenous depression has a multi-factor etiology, with hereditary, organic and psychodynamic factors operating in the early part of life, and a precipitating factor at the time of crisis. Melancholia is a psychosomatic disease. Just as a peptic ulcer caused by psychological factors must be treated somatically as well as psychologically, so the same principle applies in melancholia. He was not sure thatpre-treatment with Tofranil reduces the required number of ECT's, but had the impression that it does. However, ECT has fewer side effects. He agreed that ECT.on an out-patient basis is quite acceptable provided one knows the patient and the surroundings in which he lives. He also agreed that sometimes the idea of admission to a mental hospital leads to suicide. However, the self-destructive tendencies associated with the disease are more important. He did not know how to separate those patients who should have Tofranil from those who should have ECT. Apparently the same group of patients tends to respond to either treatment. In general, he starts Tofranil treatment if the patient is afraid to have electroshock. This gives time for patient and doctor to know each other, after which the patient will have ECT with less fear. Tofrjinil is sometimes successful in patients who do not respond to ECT, and is also useful during the inevitable period of wavering/immediately after the patients are discharged from hospital.
